Claims
- 1) A compound of formula I
- 2) A compound of claim 1 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, monoalkylamino of one to six carbon atoms or dialkylamino in which each alkyl group has one to six carbon atoms.
- 3) A compound of claim 1 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms.
- 4) A compound of claim 1 wherein R2 is hydrogen, amino, monoalkylamino of one to six carbon atoms, dialkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atom.
- 5) A compound of claim 1 wherein R2 is hydrogen, or alkyl of one to six carbon atom.
- 6) A compound of claim 1 wherein X and Y are each CH.
- 7) A compound of claim 1 wherein Z is a radical of formula II or III.
- 8) A compound of claim 7 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms; R2 is hydrogen, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atom, and Z is a radical of formula II.
- 9) A compound of claim 8 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R2 is hydrogen, or alkyl of one to six carbon atom, and X and Y are CH.
- 10) A compound of claim 7 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms; R2 is hydrogen, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atom, and Z is a radical of formula III, R5 is hydroxy and R6 is Ar; or R5 is hydrogen and R6 is benzoyl, 1-benzimidazol-2-one, benzoisothiazole, benzisoxazole each optionally substituted or —(CH2)mQ.
- 11) A compound of claim 10 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R2 is hydrogen, or alkyl of one to six carbon atom, X and Y are CH; and m is 0 or 1.
- 12) A compound of claim 1 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms; R2 is hydrogen, amino, mono- or di-alkylamino in which each alkyl group has one to six carbon atoms, or alkyl of one to six carbon atom, and Z is a radical of formula IV.
- 13) A compound of claim 12 wherein R1 is hydrogen, halo, trifluoromethyl, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R2 is hydrogen, or alkyl of one to six carbon atom and X and Y are CH.
- 14) The compound of claim 1 which is 8-[2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-ylmethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan4-one or a pharmaceutically acceptable salt thereof.
- 15) The compound of claim 1 which is 8-{[8-methyl-2,3-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl]methyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one or a pharmaceutically acceptable salt thereof.
- 16) The compound of claim 1 which is 1-(1-{[8-methyl-2,3-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl]methyl}piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one or a pharmaceutically acceptable salt thereof.
- 17) The compound of claim 1 which is 8-methyl-2-(piperidin-1-ylmethyl)-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 18) The compound of claim 1 which is (4-fluorophenyl)(1-{[8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}-4-piperidinyl)methanone or a pharmaceutically acceptable salt thereof.
- 19) The compound of claim 1 which is 1-{[8-methyl-2,3-dihydro[1,4]-dioxino-[2,3-f]-quinolin-2-yl]methyl}-4-[3-(trifluoromethyl)phenyl]-4piperidinol or a pharmaceutically acceptable salt thereof.
- 20) The compound of claim 1 which is 1-{[8-methyl-2,3-dihydro[1,4]-dioxino[2,3-f]quinolin-2-yl]methyl}4-phenyl-4-piperidinecarbonitrile or a pharmaceutically acceptable salt thereof.
- 21) The compound of claim 1 which is 8-methyl-2-{[4-phenyl-3,6-dihydro-1-(2H)-pyridinyl]methyl}-2,3-dihydro[1,4]dioxino[2,3-f]quinoline or a pharmaceutically acceptable salt thereof.
- 22) The compound of claim 1 which is 8-{[8-ethyl-2,3-dihydro[1,4]dioxino-[2,3-f]quinolin-2-yl]methyl}-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one or a pharmaceutically acceptable salt thereof.
- 23) A method of treating a subject suffering from a condition selected from the group consisting of cognitive dysfunction, neurodegenerative disease, or schizophrenia which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 24) The method of claim 23 wherein the subject is a human.
- 25) A method of treating a subject suffering from a condition selected from the group consisting of anxiety, aggression and stress which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 26) The method of claim 25 wherein the subject is a human,
- 27) A method of treating a subject suffering from a condition selected from the group consisting of eating disorders, disorders of thermoregulation, sleep dysfunction and sexual dysfunction which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 28) The method of claim 27 wherein the subject is a human.
- 29) A method of treating a subject suffering depression comprising providing to the subject suffering from said condition, an antidepressant amount of a serotonin selective reuptake inhibitor and an amount of a compound of formula I
- 30) The method of claim 29 wherein the subject is a human.
- 31) The method of claim 29 wherein the serotonin selective reuptake inhibitor is sertraline, fluvoxamine, paroxetine, venlafaxine, duloxetine, citalopram, fluoxetine or metabolites thereof.
- 32) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- 33) The composition of claim 32 further comprising an antidepressant amount of a serotonin selective reuptake inhibitor.
- 34) The composition of claim 33 wherein the selective reuptake inhibitor is sertraline, fluvoxamine, paroxetine, venlafaxine, duloxetine, citalopram, fluoxetine or metabolites thereof.
Parent Case Info
[0001] This application claims priority from co-pending provisional application serial No. 60/286,567, filed on Apr. 26, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60286567 |
Apr 2001 |
US |